Valion Bio (VBIO) Other Non-Current Liabilities (2025 - 2026)
Valion Bio (VBIO) posted quarterly Other Non-Current Liabilities of $48000.0 for Q4 2025.
Valion Bio (VBIO) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Valion Bio's Other Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $48000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $48000.0; the TTM figure through Dec 2025 stood at $48000.0 (changed N/A YoY), while the FY2025 annual figure was $48000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $48000.0.
- The five-year high for Other Non-Current Liabilities was $48000.0 in Q4 2025, with the low at $48000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - |
| 10 | Valion Bio | 408,979.63 | -1.79 Mn | -45,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 454,000.00 |
| Dec 31, 2025 | 48,000.00 |